Andrea S. Blevins Primeau, PhD, MBA

Andrea S. Blevins Primeau, PhD, MBA, is a freelance medical writer and editor based in central Pennsylvania. She enjoys writing about a variety of topics including oncology, cardiovascular disease, and autoimmune disorders. Previously, she conducted research investigating the role of pharmacogenetics on the efficacy of oncologic therapies.

All articles by Andrea S. Blevins Primeau, PhD, MBA

Researchers interpreting results from studies using adaptive randomization must be aware of assumpti

General Oncology

Underrepresentation of Women in Clinical Trials Persists

By

Andrea S. Blevins Primeau, PhD, MBA

October 16, 2020

Clinical trials leading to US FDA approvals of anticancer therapies continue to underrepresent women.

A novel patient-centered approach aids the collection of research on a rare cancer.

General Oncology

New Data Resource for Studying Antitumor Immunity

By

Andrea S. Blevins Primeau, PhD, MBA

October 15, 2020

A model of tumor epitope immunogenicity has been developed that is available to the research community for studying antitumor immunity.

A randomized phase 3 trial has shown that a chemoradiotherapy boost following concurrent chemotherap

NSCLC Responds to Brigatinib After Other ALK TKIs

By

Andrea S. Blevins Primeau, PhD, MBA

October 14, 2020

Brigatinib demonstrated antitumor activity among patients with progressive NSCLC with ALK alterations after treatment with other next-generation ALK TKIs.

Colorectal Cancer in Young People

By

Andrea S. Blevins Primeau, PhD, MBA

October 9, 2020

This fact sheet discusses the rising incidence of colorectal cancer among young adults.

Regardless of the efficacy of immune checkpoint inhibition in some settings, many cancers will not respond to treatment with them.

ESMO Virtual Congress 2020 Lung Cancer In-depth

Characterization of Predictors of Response or Resistance to ICIs in NSCLC

By

Andrea S. Blevins Primeau, PhD, MBA

October 6, 2020

PD-L1 expression density and cytotoxic T cells were identified as potential biomarkers for outcomes with ICIs in patients with NSCLC.

Oral S-1 with cisplatin may not be inferior compared to docetaxel with cisplatin in advanced NSCLC.

ESMO Virtual Congress 2020 Lung Cancer In-depth

Apatinib Plus Gefitinib Improved PFS in EGFR-Mutated NSCLC

By

Andrea S. Blevins Primeau, PhD, MBA

October 6, 2020

The addition of apatinib to gefitinib prolonged PFS compared with gefitinib among treatment-naive patients with EGFR-mutated NSCLC.

Patient receiving radiation therapy for cancer treatment in linear acelerator

ESMO Virtual Congress 2020 Lung Cancer In-depth

No Benefit, Higher Toxicities With Postoperative Conformal RT in Stage IIIAN2 NSCLC

By

Andrea S. Blevins Primeau, PhD, MBA

October 6, 2020

The use of modern postoperative conformal radiotherapy did not improve DFS and was associated with toxicities among patients with stage IIIAN2 NSCLC.

Neoadjuvant chemotherapy was found to negatively impact survival in resectable malignant pleural mesothelioma.

ESMO Virtual Congress 2020 Lung Cancer In-depth

Longitudinal NGS May Identify Patients At Risk for Hyperprogression or Death From ICIs

By

Andrea S. Blevins Primeau, PhD, MBA

October 6, 2020

NGS of longitudinal samples from patients with advanced NSCLC receiving ICIs identified changes associated with hyperprogression and early death.

ESMO Virtual Congress 2020 Lung Cancer In-depth

KRAS Inhibitor Shows Favorable Activity in Advanced NSCLC

By

Andrea S. Blevins Primeau, PhD, MBA

October 5, 2020

Results from a phase 1 trial suggest a KRASG12C inhibitor has a favorable safety profile and antitumor activity in advanced NSCLC.

A new study finds that blood-based measures of TMB correlate with response to pembrolizumab-based therapy in advanced lung cancer.

ESMO Virtual Congress 2020 Lung Cancer In-depth

Characteristics and Treatment Patterns of KRASG12C-Mutated NSCLC

By

Andrea S. Blevins Primeau, PhD, MBA

October 5, 2020

An analysis of from the Flatiron Health Network found that some patients with NSCLC with a KRASG12C mutation do not receive systemic therapy.

Next post in ESMO Virtual Congress 2020 Lung Cancer In-depth

Regardless of the efficacy of immune checkpoint inhibition in some settings, many cancers will not respond to treatment with them.

Characterization of Predictors of Response or Resistance to ICIs in NSCLC